Business Wire08.03.17
Avedro Inc., an ophthalmic pharmaceutical and medical device company and leader in corneal remodeling, has elected Donald J. Zurbay to its board of directors.
A veteran finance executive with more than 27 years in financial operations and accounting, Zurbay is the former vice president and chief financial officer of St. Jude Medical Inc., a Fortune 500 multi-national medical device company acquired by Abbott Laboratories for $25 billion earlier this year. During his tenure at St. Jude Medical, Zurbay helped guide the company through significant growth and expansion, including 19 acquisitions, and ultimately the recent transaction merging St. Jude Medical with Abbott.
“Don is an accomplished business leader with a proven track record of developing strategy and driving execution for business growth. He will be a superb advisor to Avedro and we are pleased to welcome him to the Board,” said Reza Zadno, Ph.D., CEO of Avedro. “Don’s guidance will be indispensable as we continue to expand our ability to deliver innovative products that dramatically improve the lives of patients with keratoconus and develop new and innovative cross-linking applications that help reduce the need for eyeglasses and contact lenses.”
“I’m thrilled to be joining Avedro’s board of directors and look forward to contributing to the business as they continue to execute their plans in expanding both in the US and internationally,” said Zurbay.
Avedro is a privately held pharmaceutical and medical device company and the leader in corneal remodeling. Avedro’s patented cross-linking technology, consisting of drug formulations and medical devices, are approved for sale in numerous countries worldwide. In the United States the company sells an orphan drug, indicated for the treatment of progressive keratoconus, which was approved by the U.S. Food and Drug Administration in 2016. Avedro continues to develop proprietary cornea cross-linking products for the treatment of keratoconus, a sight-threatening disease, and for refractive correction. The company is based in Waltham, Mass.
A veteran finance executive with more than 27 years in financial operations and accounting, Zurbay is the former vice president and chief financial officer of St. Jude Medical Inc., a Fortune 500 multi-national medical device company acquired by Abbott Laboratories for $25 billion earlier this year. During his tenure at St. Jude Medical, Zurbay helped guide the company through significant growth and expansion, including 19 acquisitions, and ultimately the recent transaction merging St. Jude Medical with Abbott.
“Don is an accomplished business leader with a proven track record of developing strategy and driving execution for business growth. He will be a superb advisor to Avedro and we are pleased to welcome him to the Board,” said Reza Zadno, Ph.D., CEO of Avedro. “Don’s guidance will be indispensable as we continue to expand our ability to deliver innovative products that dramatically improve the lives of patients with keratoconus and develop new and innovative cross-linking applications that help reduce the need for eyeglasses and contact lenses.”
“I’m thrilled to be joining Avedro’s board of directors and look forward to contributing to the business as they continue to execute their plans in expanding both in the US and internationally,” said Zurbay.
Avedro is a privately held pharmaceutical and medical device company and the leader in corneal remodeling. Avedro’s patented cross-linking technology, consisting of drug formulations and medical devices, are approved for sale in numerous countries worldwide. In the United States the company sells an orphan drug, indicated for the treatment of progressive keratoconus, which was approved by the U.S. Food and Drug Administration in 2016. Avedro continues to develop proprietary cornea cross-linking products for the treatment of keratoconus, a sight-threatening disease, and for refractive correction. The company is based in Waltham, Mass.
